Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 6Advanced Solid Tumors 5Advanced Solid Tumour 4Small Cell Lung Carcinoma 3Recurrence 3Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Multiple Myeloma 2Esophageal Squamous Cell Carcinoma 2Advanced Solid Tumor 2Unresectable Locally Recurrent Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Non-small Lung Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Metastatic Solid Tumors 1Lung Neoplasms 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Idiopathic Pulmonary Fibrosis 1

Interventions

toripalimab 1Premedication 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × Injections × 30 days × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡